Ann Thor, MD
Professor, Pathology

Website
Website
Photo
Download CV
Medical School:
  • MD, Vanderbilt University School of Medicine (1981)
Undergraduate School:
  • BS, University of California–Berkeley (CA) (1977)
Residency:
  • Vanderbilt University Medical Center Program, Pathology (1983)
Fellowships:
  • University of California (San Francisco) Program, Cytopathology (1987)
Languages: English
Department: Pathology

Professional Titles

  • Chair of Pathology
  • Chair

Recognition & Awards

  • President, Association of Pathology Chairs (2012)
  • Chair, Women in Cancer Research (2010)

Publications

  • Wahdan-Alaswad RS, Edgerton SM, Kim HM, Tan AC, Haugen BR, Liu B, Thor AD. Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer. Cell Cycle. 2023 Sep 18;:1-20. [Epub ahead of print] PubMed PMID: 37723865
  • Lyu H, Shen F, Ruan S, Tan C, Zhou J, Thor AD, Liu B. HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel. Cancer Cell Int. 2023 Sep 16;23(1):204. PubMed PMID: 37716943
  • Lipscomb MF, Joste NE, Markwood M, Bailey DN, Hansel DE, Jorda M, Leonard DGB, Powell D, Rojiani AM, Shin SJ, Thor A. Gender differences in appointments to pathology department interim chair positions and subsequent advancement to permanent chair positions. Acad Pathol. 2023 Apr-Jun;10(2):100082. PubMed PMID: 37168284
  • Liu S, Polsdofer EV, Zhou L, Ruan S, Lyu H, Hou D, Liu H, Thor AD, He Z, Liu B. Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. Mol Ther Oncolytics. 2021 Jun 25;21:303-314. PubMed PMID: 34141868
  • Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan 15;27(2):585-597. PubMed PMID: 33097494
  • Wahdan-Alaswad RS and Thor AD. Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions. InTech Open Book Chapter Metformin. Feb 12, 2020. DOI: 10.5772/intechopen.91183.
  • Wahdan-Alaswad RS, Liu B, Thor AD. Targeted Lapatinib Anti-HER2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem. Cancer Drug Resistance. 2020; 3:179-198. DOI:10.20517/cdr.2019.92.
  • Wahdan-Alaswad RS, Edgerton SM, Salem H, Kimg HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers Clin Cancer Res. 27:585–97, 2021, doi: 10.1158/1078-0432.CCR-20-2647. [Epub ahead of print] PubMed PMID: 33097494.
  • Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
  • Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, Edwards DP, MacLean PS, Schedin P. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018 Jun 14;20(1):50. PubMed PMID: 29898754
  • Wahdan-Alaswad RS, Edgerton SM, Salem HS, Thor AD. Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res. 2018;4(1). PubMed PMID: 29780974
  • Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Sci Rep. 2018 May 1;8(1):6829. PubMed PMID: 29717218
  • Howell LP, Lyons ML, Thor A, Dandar V. Sex Differences in Workplace Satisfaction and Engagement of Academic Pathologists: Opportunities to Enhance Faculty Diversity. Arch Pathol Lab Med. 2014 Dec 15. [Epub ahead of print] PubMed PMID: 25506812
  • Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014 Dec;5(6):374-89. PubMed PMID: 25213330
  • Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, Thor AD, Borges VF, Schedin P. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res. 2014 Mar 28;16(2):R31. PubMed PMID: 24678808
  • Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22;16(1):R7. PubMed PMID: 24451109
  • Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014 Feb;7(2):199-210. PubMed PMID: 24322659
  • Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res. 2013 Oct 29;15(5):R101. [Epub ahead of print] PubMed PMID: 24168763
  • Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013 Dec 15;12(24):3759-69. PubMed PMID: 24107633
  • Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 1;19(5):1281-9. PubMed PMID: 23340303
  • Kar A, Koto K, Walker D, Trudeau T, Edgerton S, Thor A, Gutierrez-Hartmann A. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+ HER2+ breast cancer patients. In press Br Cancer Res Treat
  • Liu S, Polsdofer EV, Zhou L, Ruan S, Lyu H, Hou D, Liu H, Thor AD, He Z, Liu B. Metformin-induced TRAIL upregulation promotes apoptosis in triple negative breast cancer and non-small cell lung cancer cells. In Press, Cancers
  • Wellberg EA, Corleto KA, Checkley LA, Jindal S, Johnson G, Higgins JA, Obeid S, Anderson SM, Thor AD, Schedine PJ, MacLean PS, Giles ED. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer. Breast Cancer Research. 24:42, 2022
View All (23 Total) View Less

Professional Memberships

  • American Association for Cancer Research, Inc., Member
  • American Association of Investigative Pathologists, Member
  • The American Society of Breast Disease, Member
  • College of American Pathologists, Member
  • International Academy of Pathology, Member

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

Specialties
  • Anatomic and Clinical, Board Certification (1987)
  • Cytopathology, Board Certification (1989)
  • Pathology, Board Certification
  • Anatomic, Board Certification
Conditions & Treatments
  • Cancers - Cancer Pathology
  • Cancers - Breast Cancer
  • Cancers

General Information

Medical Schools:
  • MD, Vanderbilt University School of Medicine (1981)
Undergraduate Schools:
  • BS, University of California–Berkeley (CA) (1977)
Residency Programs:
  • Vanderbilt University Medical Center Program, Pathology (1983)
Fellowships:
  • University of California (San Francisco) Program, Cytopathology (1987)
Download CV
Languages: English
Department: Pathology
;